Are compounded GLP-1s really safe and widely available?

What did @chaseveryday actually say?

The creator made two central claims: first, that compounded GLP-1 medications are legally permitted while the drugs remain on the FDA shortage list because there is no patent infringement during a shortage. Second, and more controversially, that once a drug comes off the shortage list, compounders can simply add B6 or B12 to "change the formula" and continue operating without legal risk. The creator framed this as a settled, no-worry situation: "In the long term, we don't have to worry about it."

The shortage-list explanation is mostly accurate in broad strokes. The B6/B12 workaround claim is where things get genuinely murky, and presenting it as a reliable legal escape hatch is an oversimplification that could mislead patients into false confidence about the long-term availability of their medication.

Does the science and regulation back this up?

The shortage-list piece is largely correct. Under 21 U.S.C. 503A and 503B, FDA-registered compounding pharmacies can produce copies of commercially available drugs when those drugs appear on the FDA Drug Shortage list, without triggering standard patent infringement claims. Semaglutide and tirzepatide have both appeared on that list, which is why compounding has been permitted.

The B12/B6 claim is where the creator goes off-script. The FDA's position, clarified in guidance documents updated in 2024, is that adding a "minor" ingredient does not automatically make a compounded product a legally distinct formulation. The agency has specifically warned that adding B12 or similar additives to semaglutide does not create a "different drug" for regulatory purposes if the core active ingredient is still replicating a patented product. There is no peer-reviewed clinical literature supporting the idea that B12 addition changes the pharmacological or regulatory identity of semaglutide or tirzepatide. The FDA removed tirzepatide from its shortage list in early 2025, and immediately moved to restrict compounding, signaling the B12 workaround has not been accepted as a legal shield.

What did they get wrong, and what did they get right?

Credit where it is due: the creator correctly explained the basic framework of why compounding is permitted during a shortage. That is accurate. The framing around patent infringement is a reasonable lay explanation, even if it is not the full legal picture.

Where this video misleads is the B6/B12 claim. Saying compounders "will just add in a B6 or a B12 and change the formula" and that patients "can keep getting our medicine" presents a contested legal strategy as settled fact. It is not settled. The FDA has explicitly challenged this approach. In March 2025, FDA issued guidance stating that compounders cannot circumvent post-shortage restrictions by adding trace ingredients. Several 503B outsourcing facilities faced enforcement letters on exactly this basis.

The creator also said coming off the shortage list "is not anticipated anytime soon." Tirzepatide came off the shortage list in early 2025. Semaglutide's status remains contested, with ongoing litigation between compounders and the FDA. Patients relying on this video for planning decisions are working with outdated information.

What should you actually know?

If you are currently on a compounded GLP-1, your access is genuinely uncertain and depends on active litigation, not a simple formulation tweak. Here is what the actual regulatory picture looks like right now.

• The FDA removed tirzepatide from the shortage list in early 2025 and has directed 503A and 503B facilities to stop compounding it, with enforcement grace periods that have already begun expiring.
• Multiple compounding pharmacies and trade groups filed lawsuits challenging the FDA's shortage determination. Courts have issued temporary injunctions in some jurisdictions, meaning access varies by state and pharmacy.
• The B12/B6 strategy is being tested in court, not established in law. Patients should not count on it as a guarantee.
• If you are on a compounded GLP-1 through a telehealth platform, ask your provider directly about their pharmacy's regulatory status and what contingency options exist if compounding is restricted in your state.
• Compounded drugs are not FDA-approved and have not been evaluated for the same safety, efficacy, or manufacturing standards as brand-name versions. That does not mean they are unsafe, but equivalency cannot be assumed.

Bottom line for FormBlends readers

This video is well-intentioned but presents a legally shaky workaround as reliable long-term policy. The shortage-list framework is real. The B12 escape hatch is not a done deal. Anyone on compounded semaglutide or tirzepatide should stay informed through their provider, not a 60-second TikTok, because the regulatory situation is moving fast and the stakes for uninterrupted access are real.